Regeneron Reaches New 52-Week High (REGN)

NEW YORK ( TheStreet) -- Regeneron Pharmaceuticals (Nasdaq: REGN) hit a new 52-week high Tuesday as it is currently trading at $121.95, above its previous 52-week high of $121.55 with 140,762 shares traded as of 10:10 a.m. ET. Average volume has been 1.4 million shares over the past 30 days.

Regeneron has a market cap of $7.18 billion and is part of the health care sector and drugs industry. Shares are up 116.9% year to date as of the close of trading on Monday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States.

TheStreet Ratings rates Regeneron as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. You can view the full Regeneron Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)